For research use only. Not for therapeutic Use.
PFI-90 is a selective inhibitor of histone demethylase (KDM3B) that inhibits PAX3-FOXO1 action. PFI-90 induces apoptosis and myogenic differentiation, resulting in the cell death increased. PFI-90 has the potential for the antitumor activity. (patent WO2021101929A1).
PFI-90 shows dose response in RH4, RH30, OSA-CL and TC-32 cells, with IC50s of 812, 3200, 1895 and 1113 nM, respectively[1]. ?
PFI-90 (3 μΜ; 24 hours) increases apoptosis in RH4 and SCMC cells[1].
| Catalog Number | I044415 |
| CAS Number | 53995-62-3 |
| Synonyms | N’-pyridin-2-ylpyridine-2-carbohydrazide |
| Molecular Formula | C11H10N4O |
| Purity | ≥95% |
| InChI | InChI=1S/C11H10N4O/c16-11(9-5-1-3-7-12-9)15-14-10-6-2-4-8-13-10/h1-8H,(H,13,14)(H,15,16) |
| InChIKey | GCZPXNWBXDWHKM-UHFFFAOYSA-N |
| SMILES | C1=CC=NC(=C1)C(=O)NNC2=CC=CC=N2 |
| Reference | [1]. KHAN, Javed, et al. Inhibitors of histone demethylases (pfi-63 and pfi-90) for the treatment of cancer and for the inhibition of histone demethylase in cells. WO2021101929A1. |
